Literature DB >> 19422646

Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome.

M Robinson1, S R Gray, M S Watson, G Kennedy, A Hill, J J F Belch, M A Nimmo.   

Abstract

The aim of the current study was to investigate the levels of interleukin-6 (IL-6), its soluble receptors (sIL-6R and sgp130) and F(2)-isoprostanes, at rest and during exercise, in patients with chronic fatigue syndrome (CFS). Six male CFS patients and six healthy controls performed an incremental exercise test to exhaustion and a submaximal exercise bout to exhaustion. Blood samples taken in the submaximal test at rest, immediately post-exercise and 24 h post-exercise were analyzed for IL-6, sIL-6R, sgp130 and F(2)-isoprostanes. A further 33 CFS and 33 healthy control participants gave a resting blood sample for IL-6 and sIL-6R measurement. During the incremental exercise test only power output at the lactate threshold was lower (P<0.05) in the CFS group. F(2)-isoprostanes were higher (P<0.05) in CFS patients at rest and this difference persisted immediately and 24 h post-exercise. The exercise study found no differences in IL-6, sIL-6R or sgp130 at any time point between groups. In the larger resting group, there were no differences in IL-6 and sIL-6R between CFS and control groups. This investigation has demonstrated that patients with CFS do not have altered plasma levels of IL-6, sIL-6R or sgp130 either at rest or following exercise. F(2)-isoprostanes, however, were consistently higher in CFS patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422646     DOI: 10.1111/j.1600-0838.2009.00895.x

Source DB:  PubMed          Journal:  Scand J Med Sci Sports        ISSN: 0905-7188            Impact factor:   4.221


  21 in total

Review 1.  Biomarkers for chronic fatigue.

Authors:  Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Brain Behav Immun       Date:  2012-06-23       Impact factor: 7.217

2.  Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology.

Authors:  Dikoma C Shungu; Nora Weiduschat; James W Murrough; Xiangling Mao; Sarah Pillemer; Jonathan P Dyke; Marvin S Medow; Benjamin H Natelson; Julian M Stewart; Sanjay J Mathew
Journal:  NMR Biomed       Date:  2012-01-27       Impact factor: 4.044

Review 3.  A neuroinflammatory model for acute fatigue during exercise.

Authors:  Nicole T Vargas; Frank Marino
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

4.  Alterations in redox homeostasis in the elite endurance athlete.

Authors:  Nathan A Lewis; Glyn Howatson; Katie Morton; Jessica Hill; Charles R Pedlar
Journal:  Sports Med       Date:  2015-03       Impact factor: 11.136

5.  Kindling and Oxidative Stress as Contributors to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  L A Jason; N Porter; J Herrington; M Sorenson; S Kubow
Journal:  J Behav Neurosci Res       Date:  2009-01-01

6.  An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Matthew Sorenson; Nicole Porter; Natalie Belkairous
Journal:  Neurosci Med       Date:  2011-03-01

7.  Dimensions of pure chronic fatigue: psychophysical, cognitive and biological correlates in the chronic fatigue syndrome.

Authors:  Daniel Neu; Olivier Mairesse; Xavier Montana; Medhi Gilson; Francis Corazza; Nicolas Lefevre; Paul Linkowski; Olivier Le Bon; Paul Verbanck
Journal:  Eur J Appl Physiol       Date:  2014-05-31       Impact factor: 3.078

8.  Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations.

Authors:  Alexandra H Mandarano; Jessica Maya; Ludovic Giloteaux; Daniel L Peterson; Marco Maynard; C Gunnar Gottschalk; Maureen R Hanson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 9.  Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome.

Authors:  Anthony L Komaroff; W Ian Lipkin
Journal:  Trends Mol Med       Date:  2021-06-07       Impact factor: 11.951

10.  Brain dysfunction as one cause of CFS symptoms including difficulty with attention and concentration.

Authors:  Benjamin H Natelson
Journal:  Front Physiol       Date:  2013-05-20       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.